BIOLINERX Ltd/S (BLRX) Given a $4.00 Price Target by HC Wainwright Analysts

HC Wainwright set a $4.00 target price on BIOLINERX Ltd/S (NASDAQ:BLRX) in a research note published on Friday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other research analysts have also recently commented on BLRX. Maxim Group reissued a buy rating and issued a $2.00 price target on shares of BIOLINERX Ltd/S in a report on Thursday. Zacks Investment Research raised BIOLINERX Ltd/S from a sell rating to a hold rating in a report on Wednesday. ValuEngine raised BIOLINERX Ltd/S from a hold rating to a buy rating in a report on Tuesday, October 16th. Finally, MED began coverage on BIOLINERX Ltd/S in a report on Wednesday, August 1st. They issued a market perform rating on the stock. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of Buy and an average target price of $2.50.

NASDAQ BLRX traded down $0.01 during trading hours on Friday, reaching $0.70. The company’s stock had a trading volume of 391,694 shares, compared to its average volume of 1,728,884. BIOLINERX Ltd/S has a 1 year low of $0.67 and a 1 year high of $1.84. The stock has a market cap of $78.77 million, a PE ratio of -2.59 and a beta of 0.87.

BIOLINERX Ltd/S (NASDAQ:BLRX) last posted its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.06) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.06). As a group, sell-side analysts predict that BIOLINERX Ltd/S will post -0.22 earnings per share for the current fiscal year.

An institutional investor recently bought a new position in BIOLINERX Ltd/S stock. Fosun International Ltd purchased a new position in BIOLINERX Ltd/S (NASDAQ:BLRX) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 1,357,415 shares of the biotechnology company’s stock, valued at approximately $1,412,000. Fosun International Ltd owned approximately 1.27% of BIOLINERX Ltd/S at the end of the most recent quarter. 34.69% of the stock is owned by hedge funds and other institutional investors.

BIOLINERX Ltd/S Company Profile

BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.

See Also: Stop Order

Receive News & Ratings for BIOLINERX Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX Ltd/S and related companies with's FREE daily email newsletter.

Leave a Reply